"Biomarker discovery is revolutionizing cancer diagnosis, treatment, and monitoring through the identification of measurable markers of disease. The biomarker discovery session centers on the newest developments in the discovery of molecular, genetic, and protein-based biomarkers that give insight into tumor behavior and patient response.".
Biomarkers have the ability to indicate cancer type, stage, progression, and possible therapy outcomes. Biomarkers are essential in early detection, stratification of patients, and individualized therapy. Methods like genomics, proteomics, metabolomics, and liquid biopsy are being utilized to detect new biomarkers with high sensitivity and specificity. This makes it possible for clinicians to adjust treatment according to individual patients, enhancing efficacy while reducing side effects.
The session also discusses the use of biomarkers in monitoring for response to treatment and for minimal residual disease. The changes over time in biomarkers can be used by clinicians to modify therapies in real-time and anticipate relapse. Computational biology and artificial intelligence are quickening the pace of biomarker discovery, allowing for quick translation from studies to bedside.
Participants will learn about new approaches in biomarker discovery, their clinical use, and future directions in precision oncology. This session emphasizes the central role of biomarkers in enhancing cancer outcomes and driving personalized, data-informed patient care.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
